🇺🇸 FDA
Pipeline program

ICI201

CICI201Y001

Phase 1 small_molecule terminated

Quick answer

ICI201 for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials